Whole Exome and Transcriptome Sequencing (WETS) for Oncology is a test to sequence the coding region of the genome from the tumor and the matched normal specimen and transcriptome sequencing of the tumor specimen. WES has superior sensitivity for calling variant types including SNVs, indels, somatic copy number alterations. In comparison to whole genome sequencing (WGS), this test includes sequencing only the protein coding regions of the genome (exons), which comprises ~1–2% of the genome that is translated into protein, and not the non-protein coding regions of the genome (introns). WETS is indicated for characterizing any tumor for molecular profiling; providing information for prognosis in primary disease, stratify patient into appropriate risk group and choose both treatment and surveillance strategies; knowledge of clinically actionable genes may inform target selection for drugs as well as eligibility in clinical trial.
For inquiries, please contact us.